Publications en collaboration avec des chercheurs de Hospital Italiano de Buenos Aires (13)

2022

  1. Guidelines on the management of mineral and bone metabolism disorders during pregnancy and lactation

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 7, pp. 530-539

2020

  1. Phosphate disorders and clinical management of hypophosphatemia and hyperphosphatemia

    Endocrinologia, Diabetes y Nutricion, Vol. 67, Núm. 3, pp. 205-215

2018

  1. Consensus document on osteoporosis in males

    Endocrinologia, Diabetes y Nutricion, Vol. 65, pp. 9-16

2017

  1. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367

  2. Recommendations on the effect of antidiabetic drugs in bone

    Endocrinologia, Diabetes y Nutricion, Vol. 64, pp. 1-6

  3. Recommended vitamin D levels in the general population

    Endocrinologia, Diabetes y Nutricion, Vol. 64, pp. 7-14

  4. Transancestral mapping and genetic load in systemic lupus erythematosus

    Nature Communications, Vol. 8

2015

  1. Multiplex Real-Time PCR Assay Using TaqMan Probes for the Identification of Trypanosoma cruzi DTUs in Biological and Clinical Samples

    PLoS Neglected Tropical Diseases, Vol. 9, Núm. 5

2013

  1. Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression

    PLoS Genetics, Vol. 9, Núm. 10

2009

  1. Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus

    Human Molecular Genetics, Vol. 18, Núm. 19, pp. 3739-3748

  2. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans

    Journal of Clinical Investigation, Vol. 119, Núm. 4, pp. 911-923

2007

  1. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus

    Arthritis and Rheumatism, Vol. 56, Núm. 4, pp. 1234-1241

1999

  1. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study

    Osteoporosis International, Vol. 9, Núm. 5, pp. 461-468